Implant risk factors analysed


Male gender, younger age related to IOP elevation after RVO treatment, study finds

Male gender and younger age were identified as risk factors for IOP elevation after dexamethasone implant (Ozurdex, Allergan) treatment in retinal vein occlusion (RVO) in a recent subset analysis, but the elevated IOP did not seem to affect improvement in visual acuity or anatomic outcomes evaluated with optical coherence tomography (OCT), according to Dr Michael Singer.

The analysis was performed to evaluate potential risk factors associated with IOP elevation after dexamethasone implant treatment and to compare the visual acuity and anatomic outcomes between patients with and without IOP elevation. It was conducted on patients who had received dexamethasone treatment in the two identical sham-controlled trials that made up the GENEVA study. This population included 298 patients with elevated IOP after single treatment or re-treatment and 535 patients without IOP elevation.

Dr Singer did not take part in the subset analysis but commented on the work from his perspective as a leading investigator and clinician who has extensive experience with the dexamethasone intravitreal implant.

Gender was the only other significant factor to emerge from the analysis. Males composed 67.8% of the group with elevated IOP but 43.2% of the group without (p < 0.001).

"If there are better ways to predict who is at risk or when they're at risk, it might decrease some of the apprehension that retina specialists have about using steroids," Dr Singer said.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.